{"id":"busulfan-busilvex","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Bone marrow suppression"},{"rate":"30-60%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL820","moleculeType":"Small molecule","molecularWeight":"246.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Busulfan works by adding an alkyl group to the DNA of cancer cells, which damages the cells' ability to replicate. This leads to cell death and ultimately, tumor shrinkage. Busulfan is particularly effective against hematological malignancies.","oneSentence":"Busulfan is an alkylating agent that interferes with DNA replication, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:57.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia"},{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT03619551","phase":"PHASE2","title":"Conditioning SCID Infants Diagnosed Early","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2018-10-22","conditions":"SCID","enrollment":56},{"nctId":"NCT03538899","phase":"PHASE1, PHASE2","title":"Autologous Gene Therapy for Artemis-Deficient SCID","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-05-31","conditions":"Severe Combined Immunodeficiency","enrollment":24},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT06506461","phase":"PHASE1","title":"Gene Editing For Sickle Cell Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-03-21","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT01512888","phase":"PHASE1, PHASE2","title":"Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-08-17","conditions":"Severe Combined Immunodeficiency Disease, X-linked","enrollment":28},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT01985061","phase":"PHASE2","title":"Evaluation of 3 Different Doses of IV Busulfan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2013-12","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":177},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT03207009","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2017-06-08","conditions":"Beta-Thalassemia","enrollment":19},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT02906202","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2016-08-08","conditions":"Beta-Thalassemia","enrollment":24},{"nctId":"NCT01860170","phase":"PHASE1, PHASE2","title":"Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2012-04","conditions":"Hematological Malignancy","enrollment":28},{"nctId":"NCT01191957","phase":"PHASE3","title":"Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2008-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":252},{"nctId":"NCT02623309","phase":"PHASE3","title":"Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2016-02-23","conditions":"Hematologic Neoplasms","enrollment":108},{"nctId":"NCT01410344","phase":"PHASE2","title":"Allogeneic Transplant in HIV Patients (BMT CTN 0903)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":"Leukemia, Lymphoma, HIV","enrollment":20},{"nctId":"NCT03600909","phase":"PHASE2","title":"A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-15","conditions":"Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)","enrollment":3},{"nctId":"NCT00881556","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-08-20","conditions":"Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT01020539","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia","enrollment":18},{"nctId":"NCT00426517","phase":"EARLY_PHASE1","title":"Donor Stem Cell Transplantation for Congenital Immunodeficiencies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01-19","conditions":"Inherited Immune Deficiencies","enrollment":48},{"nctId":"NCT00005797","phase":"PHASE2","title":"Bone Marrow Transplant in Treating Patients With Hematologic Cancers","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"1993-03","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms","enrollment":125},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT00822770","phase":"PHASE1, PHASE2","title":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-01","conditions":"Stem Cell Transplantation, Leukemia","enrollment":47},{"nctId":"NCT00836628","phase":"PHASE1","title":"Study of Busulfan for Refractory Central Nervous System (CNS) Tumors","status":"WITHDRAWN","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-07","conditions":"Refractory Brain Tumors","enrollment":""},{"nctId":"NCT00997386","phase":"PHASE2","title":"Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2009-09","conditions":"Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic","enrollment":16},{"nctId":"NCT00943319","phase":"PHASE1, PHASE2","title":"Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":50},{"nctId":"NCT02483325","phase":"PHASE2","title":"Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2014-09","conditions":"Hematological Diseases","enrollment":33},{"nctId":"NCT02057770","phase":"PHASE1","title":"Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-02-28","conditions":"Leukemia, Myeloid, Acute","enrollment":25},{"nctId":"NCT02354443","phase":"PHASE1","title":"A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2015-06","conditions":"Metabolic Disorders","enrollment":1},{"nctId":"NCT02333838","phase":"PHASE2","title":"Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-05","conditions":"Leukemia, Myeloid","enrollment":31},{"nctId":"NCT01572181","phase":"PHASE2","title":"Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-04","conditions":"Hematologic Malignancy","enrollment":50},{"nctId":"NCT02130869","phase":"PHASE1","title":"A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-10-10","conditions":"Neuroblastoma, Lymphoma, High-risk Tumor","enrollment":8},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT01916252","phase":"PHASE3","title":"Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2013-09","conditions":"Multiple Myeloma","enrollment":460},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT00555048","phase":"PHASE1, PHASE2","title":"Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-09","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT00934232","phase":"PHASE1","title":"Busulfan in Multiple Myeloma","status":"TERMINATED","sponsor":"Guido Tricot","startDate":"2009-08","conditions":"Multiple Myeloma","enrollment":13},{"nctId":"NCT00800839","phase":"PHASE2","title":"Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-09","conditions":"Hematologic Diseases, Leukemia, Lymphoma","enrollment":56},{"nctId":"NCT02469974","phase":"NA","title":"Ruxolitinib in Combination With Autotransplant","status":"WITHDRAWN","sponsor":"Marina Kremyanskaya","startDate":"2015-05","conditions":"Myelofibrosis, MF","enrollment":""},{"nctId":"NCT00670410","phase":"PHASE1","title":"Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2003-11","conditions":"Neuroblastoma","enrollment":15},{"nctId":"NCT00618969","phase":"PHASE2","title":"Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2008-02","conditions":"Hematologic Neoplasms, Anemia, Aplastic, Hemoglobinuria, Paroxysmal","enrollment":2},{"nctId":"NCT00423826","phase":"","title":"Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-01","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00582933","phase":"PHASE2","title":"Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-05","conditions":"Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT02531841","phase":"PHASE3","title":"High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma","status":"UNKNOWN","sponsor":"University Hospital Freiburg","startDate":"2014-07","conditions":"Diffuse Large B-cell-lymphoma","enrollment":250},{"nctId":"NCT00402558","phase":"PHASE1","title":"Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":15},{"nctId":"NCT01203228","phase":"PHASE3","title":"Dose-reduced Versus Standard Conditioning in MDS/sAML","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2004-05","conditions":"Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia","enrollment":129},{"nctId":"NCT01009840","phase":"PHASE2","title":"IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT00093587","phase":"NA","title":"Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2004-08","conditions":"Graft Versus Host Disease, Leukemia","enrollment":""},{"nctId":"NCT01923935","phase":"PHASE2","title":"Busulfan and Melphalan Conditioning in Multiple Myeloma","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2013-01","conditions":"Multiple Myeloma","enrollment":105},{"nctId":"NCT00795132","phase":"PHASE2","title":"Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-04","conditions":"Acute Leukaemia, Chronic Disease, Leukemia","enrollment":47},{"nctId":"NCT00054327","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-11","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":34},{"nctId":"NCT01255527","phase":"PHASE1, PHASE2","title":"Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-10","conditions":"Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation","enrollment":53},{"nctId":"NCT00852163","phase":"PHASE2","title":"Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2007-03","conditions":"Leukemia, Myelodysplastic Syndrome","enrollment":20},{"nctId":"NCT00002547","phase":"PHASE2","title":"Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"1987-08","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":280},{"nctId":"NCT00774280","phase":"PHASE3","title":"Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2002-05","conditions":"Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT00815568","phase":"PHASE2","title":"Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2008-08","conditions":"AML, MDS, ALL","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"busulfan (Busilvex ®)","genericName":"busulfan (Busilvex ®)","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Busulfan is an alkylating agent that interferes with DNA replication, leading to cell death. Used for Chronic myeloid leukemia, Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}